Novo Nordisk (NOVOB DC) wegovy pill 25mg showed greater mean weight loss vs. Orforglipron (LLY) 36mg in population-adjusted indirect treatment comparison
- Population-adjusted indirect treatment comparison uses data from oasis 4 & attain-1 clinical trials.
- In separate patient preference study, 84% favoured wegovy pill 25mg-like treatment profile vs. Orforglipron-like profile.
- Orforglipron 36mg treatment had about 14 times higher discontinuation odds due to gastrointestinal adverse events vs wegovy pill 25mg.
Context
Novo Nordisk's Wegovy pill demonstrated superior efficacy in weight loss compared to Eli Lilly's Orforglipron in a population-adjusted comparison, highlighting a potential competitive advantage. Additionally, a strong preference among patients for Wegovy, combined with significantly lower discontinuation rates due to side effects, suggests that Novo Nordisk may see enhanced market positioning and demand in the weight loss segment, which could positively impact their revenues.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#ELI LILLY & CO#LLY.US#NOVO NORDISK A/S#NOVOB.DC#EQUITIES#EU SESSION#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#EUROPEAN EQUITIES